Tolcapone Improves Cognition and Cortical Information Processing in Normal Human Subjects
The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
Abstract
Prefrontal cortical dopamine (DA) regulates various executive cognitive functions, including attention and working memory. Efforts to enhance prefrontal-related cognition, which have focused on catecholaminergic stimulant drugs, have been unsatisfactory. Recently, the demonstration that a functional polymorphism in the catecholamine-O-methyltransferase (COMT) gene impacts prefrontal cognition raises the possibility of a novel pharmacological approach for the treatment of prefrontal lobe executive dysfunction. To explore in a proof of concept study the effects of tolcapone, a CNS penetrant specific COMT inhibitor, we performed a randomized, double blind, placebo controlled, and crossover design of this drug in normal subjects stratified by COMT (val158met) genotype. COMT enzyme activity was determined in peripheral blood. Forty-seven normal volunteers with no family history of psychiatric disorders underwent neuropsychological testing and 34 of those subjects underwent physiological measurement of prefrontal information processing assessed by blood oxygen level-dependent functional magnetic resonance imaging (fMRI). We found significant drug effects on measures of executive function and verbal episodic memory and a significant drug by genotype interaction on the latter, such that individuals with val/val genotypes improved, whereas individuals with met/met genotypes worsened on tolcapone. fMRI revealed a significant tolcapone-induced improvement in the efficiency of information processing in prefrontal cortex during a working memory test. This study demonstrates enhancement of prefrontal cortical function in normal human subjects with a nonstimulant drug having COMT inhibitory activity. Our results are consistent with data from animal studies and from computational models of the effects of selective enhancement of DA signaling in the prefrontal cortex.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“increasing dopamine activity in the mPFC improved set-shifting in humans (Apud et al 2007).”
From Prefrontal cortex executive processes affected by stress in health and disease (2018) · cites this paper as Apud et al 2007
In the citing paper
“For example, increasing DA levels in individuals who have high baseline DA levels impairs cognitive performance, (perhaps pushing them over the peak of the inverted U curve) whereas improvements are noted in individuals with lower baseline levels (pushing them closer to the apex of the curve) (Mattay, Goldberg et al. 2003; Apud, Mattay et al. 2007; Cools, Frank et al. 2009).”
From Developmental imaging genetics: Linking dopamine function to adolescent behavior (2014) · cites this paper as Apud, Mattay et al. 2007
In the citing paper
“Furthermore, increasing DA levels interacts with the COMT val158met SNP consistent with the putative inverted U model with met individuals demonstrating diminished cortical efficiency during tasks of cognitive control and val individuals demonstrating improvements (Mattay, Goldberg et al. 2003; Apud, Mattay et al. 2007).”
From Developmental imaging genetics: Linking dopamine function to adolescent behavior (2014) · cites this paper as Apud, Mattay et al. 2007
Citations
Cites
Effect of COMT Val 108/158 Met genotype on frontal lobe function and risk for schizophrenia
Egan, M. F., Goldberg, T. E., Kolachana, B. S., Callicott, J. H., Mazzanti, C. M., Straub, R. E., Goldman, D., & Weinberger, D. R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.111134598 · Cited by 2,381 · cited 6×
“This genetic effect has been demonstrated in humans for performance on a variety of cognitive tests, such as working memory and executive function (Egan et al, 2001; Ho et al, 2005) as well as prefrontal physiology as assessed by functional magnetic resonance imaging (fMRI) (Egan et al, 2001;…”
BackgroundMethodInfluentialSelf-citationChen, J., Lipska, B. K., Halim, N., Ma, Q. D., Matsumoto, M., Melhem, S., Kolachana, B. S., Hyde, T. M., Herman, M. M., Apud, J., et al. (2004) · The American Journal of Human Genetics · doi:10.1086/425589 · Cited by 1,675 · cited 3×
“COMT val158met (rs4680 G to A) genotyping was determined using Taqman 50-exonuclease allelic discrimination assay (Applied Biosystems, Foster City, CA) as described elsewhere (Chen et al, 2004).”
BackgroundMethodSelf-citationThe principal features and mechanisms of dopamine modulation in the prefrontal cortex
Seamans, J. K., & Yang, C. R. (2004) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2004.05.006 · Cited by 1,592 · cited 2×
“There are also reports that COMT genotype affects function on declarative memory tests referable to processing in temporal lobe structures implicated in long-term memory (de Frias et al, 2004) Converging evidence from electrophysiological studies in experimental animals indicates that DA focuses and stabilizes prefron…”
BackgroundMendelian Proportions in a Mixed Population
Hardy, G. H. (1908) · Science · doi:10.1126/science.28.706.49 · Cited by 1,339
Männistö, P. T., & Kaakkola, S. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01423-6 · Cited by 1,068 · cited 2×
“0 h after administration of tolcapone and maximum inhibition of COMT activity in red blood cells is achieved between 1 and 4 h following administration of the drug (Jorga et al, 1999; Jorga, 1998; Mannisto and Kaakkola, 1999).”
BackgroundInfluentialMattay, V. S., Goldberg, T. E., Fera, F., Hariri, A. R., Tessitore, A., Egan, M. F., Kolachana, B., Callicott, J. H., & Weinberger, D. R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0931309100 · Cited by 893 · cited 9×
“In fact, the effects of amphetamine on prefrontal efficiency measured with fMRI (Mattay et al, 2003) were more noticeable in val/val individuals, a group with putatively higher COMT activity in the frontal cortex and, hence, relatively lower DLFPC synaptic DA concentrations.”
BackgroundMethodInfluentialSelf-citationGogos, J. A., Morgan, M., Luine, V., Santha, M., Ogawa, S., Pfaff, D., & Karayiorgou, M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.17.9991 · Cited by 864 · cited 4×
“…release or metabolism, studies of COMT knock-out mice and of COMT inhibitors in rodents indicate that COMT has little impact on norepinephrine flux in prefrontal cortex, perhaps because of the abundance of functional norepinephrine transporters (Gogos et al, 1998; Tunbridge et al, 2004).”
BackgroundResultInfluentialAuditory Working Memory and Wisconsin Card Sorting Test Performance in Schizophrenia
Gold, J. M. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830140071013 · Cited by 819 · cited 2×
“…to COMT genotype (notably, N Back, CPT, verbal memory, ID/ED), engage prefrontal cortical processes, and/or demonstrate a response to psychostimulant medication (notably verbal fluency, trail making and letter number span) (D’Esposito et al, 2000; Gold et al, 1997; Gourovitch et al, 2000).”
BackgroundPrefrontal cortical contributions to working memory: evidence from event-related fMRI studies
D'Esposito, M., Postle, B. R., & Rypma, B. (2000) · Experimental Brain Research · doi:10.1007/s002210000395 · Cited by 794 · cited 2×
“…to COMT genotype (notably, N Back, CPT, verbal memory, ID/ED), engage prefrontal cortical processes, and/or demonstrate a response to psychostimulant medication (notably verbal fluency, trail making and letter number span) (D’Esposito et al, 2000; Gold et al, 1997; Gourovitch et al, 2000).”
BackgroundPrefrontal neurons and the genetics of schizophrenia
Weinberger, D. R., Egan, M. F., Bertolino, A., Callicott, J. H., Mattay, V. S., Lipska, B. K., Berman, K. F., & Goldberg, T. E. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01252-5 · Cited by 741 · cited 1×
“This drug by genotype effect is consistent with relatively lower prefrontal cortical DA signaling in these subjects and presumed benefit of enhanced prefrontal DA in this context (Mattay et al, 2003; Weinberger et al, 2001).”
BackgroundSelf-citation
Research works printed but not linked: 3
- McNair D, Lorr M (1981). ITS Manual for the Profile of Mood States. Multi-health System, Inc.: San Diego, CA.
- Weinberg W (1908). ber den Nachweis der Vererbung beim Menschen. Jahresh Ver Vaterl Naturk Württemb 64: 368–382.
- Zurcher G, Dingemanse J, Da Prada M (1991). Ro-40-7592, A Potent Inhibitor of Extracerebral and Brain Catechol-O-methyltransferase: Preclinical and Clinical Findings. John Libbey SRL: Rome.
Cited by
Items 101–200 of 246
Tolcapone addition improves Parkinson’s disease associated nonmotor symptoms
Müller, T. H., & for the TANIMOS Study Investigators (2013) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285613512392 · Cited by 26
“This brain task is related to a predominant cholinergic deficit and is less dopamine sensitive [Apud et al. 2007].”
BackgroundLee, T.-W., Yu, Y. W., Hong, C., Tsai, S.-J., Wu, H.-C., & Chen, T.-J. (2011) · Brain Research · doi:10.1016/j.brainres.2010.12.073 · Cited by 24
Tolcapone-Enhanced Neurocognition in Healthy Adults: Neural Basis and Predictors
Bhakta, S. G., Light, G. A., Talledo, J., Balvaneda, B., Hughes, E., Álvarez, A., Rana, B. K., Young, J. W., & Swerdlow, N. R. (2017) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx074 · Cited by 26
“, 2008), and reduce prefrontal cortical blood oxygen-dependent signaling during working memory and attention tasks (Apud et al., 2007; Magalona et al., 2013) in HS.”
BackgroundHsieh, K., Plascencia‐Villa, G., Lin, K., Perry, G. L., Jiang, X., & Kim, Y. (2022) · iScience · doi:10.1016/j.isci.2022.105678 · Cited by 28
“Memantine is usually administered in combination with Donepezil, but in combination with Tolcapone, the drugs could have significant benefits on global and functional outcomes in AD subjects.(38,39)”
BackgroundFuture perspectives on the treatment of cognitive deficits and negative symptoms in schizophrenia
GOFF, D. C. (2013) · World Psychiatry · doi:10.1002/wps.20026 · Cited by 27
“The COMT inhibitor, tolcapone, has been shown to improve cognitive function in healthy subjects, predicted by COMT genotype (103), and may represent a potential therapeutic approach in schizophrenia.”
BackgroundRasagiline in the Treatment of the Persistent Negative Symptoms of Schizophrenia
Buchanan, R. W., Weiner, E., Kelly, D. L., Gold, J. M., Keller, W. R., Waltz, J. A., McMahon, R. P., & Gorelick, D. A. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu151 · Cited by 26
Gupta, M., Kaur, H., Jajodia, A., Jain, S., Satyamoorthy, K., Mukerji, M., Thirthalli, J., & Kukreti, R. (2011) · Current Molecular Medicine · doi:10.2174/156652411798062386 · Cited by 28
“Further, the effect of tolcapone can be genotype dependent as normal subjects with Val/Val genotype (rs4680) showed significant performance enhancement, whereas Met homozygotes worsened on tolcapone treatment [117].”
BackgroundMicoulaud, F. G. (2015) · Journal of Clinical Research & Bioethics · doi:10.4172/2155-9627.1000213 · Cited by 29
“Tolcapone (200 mg single dose) has been found to significantly improve executive function and verbal episodic memory performances in healthy adults [62,63].”
BackgroundValomon, A., Holst, S. C., Borrello, A., Weigend, S., Müller, T., Berger, W., Sommerauer, M., Baumann, C. R., & Landolt, H. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0018-8 · Cited by 25
“Indeed, previous research consistently concluded that this compound may improve distinct aspects of cognitive functions in Parkinson’s patients [36] and in healthy volunteers [10, 11, 13], as well as in rats and mice [12, 37, 38].”
BackgroundResultInfluentialEffects of Dopaminergic Drugs on Cognitive Control Processes Vary by Genotype
Furman, D. J., White, R. L., Naskolnakorn, J. R., Ye, J., Kayser, A. S., & D’Esposito, M. (2020) · Journal of Cognitive Neuroscience · doi:10.1162/jocn_a_01518 · Cited by 26
“…stability, including the n-back task (Farrell et al., 2012; Giakoumaki, Roussos, & Bitsios, 2008) and the intradimensional set-shifting task (Apud et al., 2007), which assesses the extent to which individuals can form and stably maintain attentional sets, and on tests of prepulse…”
InfluentialGrant, J. E., Hook, R., Valle, S., Chesivoir, E., & Chamberlain, S. R. (2021) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000368 · Cited by 24
Miskowiak, K. W., Yalın, N., Seeberg, I., Burdick, K. E., Balanzá‐Martínez, V., Bonnín, C. D. M., Bowie, C. R., Carvalho, A. F., Dols, A., Douglas, K. M., et al. (2022) · Bipolar Disorders · doi:10.1111/bdi.13247 · Cited by 24
“Cognitive outcome measures MRI technique & strength Main findings Quality rating Alda et al Apud et al. 2007 Double- blind cross- over RCT 1st day- 300 mg/day tolcapone 2nd- 7th day- 600 mg/day tolcapone 34 N/A, inclusion criteria: 18– 55 51% n- back task Task fMRI 3T No significant difference…”
InfluentialHerman, A. I., Jatlow, P. I., Gelernter, J. E., Listman, J. B., & Sofuoglu, M. (2013) · The Pharmacogenomics Journal · doi:10.1038/tpj.2013.1 · Cited by 24
Tian, T., Qin, W., Liu, B., Wang, D., Wang, J., Jiang, T., & Yu, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078697 · Cited by 26
“Pharmacological studies in both animals [102] and humans [14,103-106] have indicated that relatively poor cognitive performance in individuals with lower DA levels tended to improve after dopamimetic agent stimulation, whereas performance of individuals with DA levels near or at the top of the inverted U-shaped curve…”
BackgroundSafinamide: an add-on treatment for managing Parkinson’s disease
Müller, T. (2018) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s137740 · Cited by 30
Warbrick, T., Mobascher, A., Brinkmeyer, J., Musso, F., Stöcker, T., Shah, N. J., Vossel, S., & Winterer, G. (2011) · Psychopharmacology · doi:10.1007/s00213-010-2145-8 · Cited by 25
“In addition, the COMT (catecholamine-O-methyltransferase) inhibitor tolcopone was shown to reduce BOLD activation in the dorsolateral prefrontal cortex in tasks involving memory and executive function; this was associated with an improvement in performance (Apud et al. 2007).”
BackgroundBarkus, C., Korn, C., Stumpenhorst, K., Laatikainen, L. M., Ballard, D., Lee, S., Sharp, T., Harrison, P. J., Bannerman, D. M., Weinberger, D. R., et al. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.119 · Cited by 27
Self-citationWestphal, A. J., Ballard, M. E., Rodriguez, N., Vega, T. A., D’Esposito, M., & Kayser, A. S. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01512-6 · Cited by 23
Detrait, E., Carr, G., Ferraille, S., Weinberger, D., & Lamberty, Y. (2016) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000208 · Cited by 19
“…functional Val158Met polymorphism on COMT and, as predicted, tolcapone has been shown to ameliorate working memory and executive dysfunctions in individuals having increased DA metabolism (Val–Val genotypes), compared with those bearing the Met–Met allele (Apud et al., 2007; Farrell et al., 2012).”
BackgroundSelf-citationRutherford, K., & Daggett, V. (2009) · Biochemistry · doi:10.1021/bi900174v · Cited by 26
“Recent studies linking the destabilizing V108M polymorphism with improved prefrontal cognition (45,46) have led to the use of several of these COMT inhibitors to improve cortical processing in individuals carrying the wild-type COMT allele (72,73).”
BackgroundAugmenting Frontal Dopamine Tone Enhances Maintenance over Gating Processes in Working Memory
Furman, D. J., Zhang, Z., Chatham, C. H., Good, M., Badre, D., Hsu, M., & Kayser, A. S. (2021) · Journal of Cognitive Neuroscience · doi:10.1162/jocn_a_01641 · Cited by 24
Santos‐García, D., Fernández‐Pajarín, G., Oropesa-Ruiz, J. M., Sevilla, F. E., Rashid-López, R., & Enríquez, J. G. M. (2022) · Brain Sciences · doi:10.3390/brainsci12030383 · Cited by 23
“Specifically, some studies with first and second generation COMT inhibitors (entacapone and tolcapone) observed a benefit by the patients on some NMS [9,10,38,39], but really the evidence is scarce, possibly in part due”
ResultSchacht, J. P., Im, Y., Hoffman, M., Voronin, K. E., Book, S. W., & Anton, R. F. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01335-z · Cited by 23
Just do it: A neuropsychological theory of agency, cognition, mood, and dopamine.
Ashby, F. G., Zetzer, H. A., Conoley, C. W., & Pickering, A. D. (2024) · Journal of Experimental Psychology General · doi:10.1037/xge0001587 · Cited by 21
“Similarly, a drug that slows DA degradation in prefrontal cortex by inhibiting the action of catechol-O-methyltransferase (COMT) was found to improve performance on a variety of executive function tasks (Apud et al., 2007).”
BackgroundNeuroimaging in Psychiatric Pharmacogenetics Research: The Promise and Pitfalls
Falcone, M., Smith, R. M., Chenoweth, M. J., Bhattacharjee, A. K., Kelsoe, J. R., Tyndale, R. F., & Lerman, C. E. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.152 · Cited by 22
van Amelsvoort, T., & Hernaus, D. (2016) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2016.00082 · Cited by 22
“These results are in line with tolcapone’s effect in healthy volunteers, where it has been reported to increase n-back performance (156) and optimize task-related brain activity (156, 157).”
Lin, C., Fan, J., Lin, H.-I., Chang, C.-W., & Wu, Y. (2018) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2018.02.015 · Cited by 23
Fremont, R., Manoochehri, M., Armstrong, N. M., Mattay, V. S., Apud, J. A., Tierney, M. C., Devanand, D. P., Gazes, Y., Habeck, C. G., Wassermann, E. M., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191265 · Cited by 21
“Notably, prior studies have shown that tolcapone treatment on the scale of 7–10 days can improve N-back performance in healthy control subjects [7, 17].”
InfluentialSelf-citationZareyan, S., Zhang, H., Wang, J., Song, W., Hampson, E., Abbott, D., & Diamond, A. D. (2020) · Cerebral Cortex · doi:10.1093/cercor/bhaa276 · Cited by 27
“Such hypotheses are consistent with findings like tolcapone (a COMT inhibitor) being found to aid the EF performance of those with a faster COMT enzyme (COMT-Vals) but to impair the EFs of those with an already slower COMT enzyme (COMT-Mets; Apud et al. 2007) and findings like amphetamine being found to enhance PFC ef…”
ResultGazzina, S., Manes, M. A., Padovani, A., & Borroni, B. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.05.056 · Cited by 22
Byers, S., Buchler, I. P., Depasquale, M. J., Rowley, H. L., Kulkarni, R. S., Pinder, L., Kolobova, A., Li, C., Au, V., Akuma, D., et al. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05566-0 · Cited by 19
“…LIBD-1 (66 nM in the brain and CSF); LIBD-2 (58 nM in CSF and 233 nM in the brain) BLQ, below limit of quantitation; N/A, no values ***p < 0.001 and ****p < 0.0001 compared with the vehicle-treated group at the same time point many clinical indications (Apud et al. 2007; Gallagher et al. 2015).”
BackgroundInfluentialExperimental Dopamine Reuptake Inhibitors in Parkinson’s Disease: A Review of the Evidence
Müller, T. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s267032 · Cited by 18
Ethical and Legal Issues in Enhancement Research on Human Subjects
Mehlman, M. J., Berg, J. W., Juengst, E. T., & Kodish, E. D. (2011) · Cambridge Quarterly of Healthcare Ethics · doi:10.1017/s0963180110000605 · Cited by 18
“detected a cognition-enhancing effect in their normal controls.(10) This raises the possibility that investigators who are concerned that they might have difficulty persuading funding agencies, government regulators, or institutional review boards (IRBs) to approve enhancement research will seek to hide enhancement re…”
BackgroundTolcapone, COMT Polymorphisms and Pharmacogenomic Treatment of Schizophrenia
Bitsios, P., & Roussos, P. (2011) · Pharmacogenomics · doi:10.2217/pgs.10.206 · Cited by 18
Kayser, A. S., Vega, T. A., Weinstein, D., Peters, J., & Mitchell, J. (2016) · NeuroImage Clinical · doi:10.1016/j.nicl.2016.12.022 · Cited by 18
“, 2004) and reduce impulsivity via increased activity within cognitive control regions, similar to its effects on aspects of workingmemory (Apud et al., 2007).”
InfluentialMagalona, S., Rasetti, R., Chen, J., Chen, Q., Gold, I., Decot, H., Callicott, J. H., Berman, K. F., Apud, J. A., Weinberger, D. R., et al. (2013) · CNS Drugs · doi:10.1007/s40263-013-0082-x · Cited by 18
“5–2 h after oral administration and maximum inhibition of COMT activity in red blood cells is reached between 1 and 4 h following administration of the drug [38, 42, 48, 49].”
BackgroundMethodSelf-citationPharmacogenetic Approaches to Cognitive Enhancement in Schizophrenia
Burdick, K. E., Gopin, C. B., & Malhotra, A. K. (2011) · Harvard Review of Psychiatry · doi:10.3109/10673229.2011.581899 · Cited by 19
Genetic biomarkers of placebo response: what could it mean for future trial design?
Hall, K. T., & Kaptchuk, T. J. (2013) · Clinical Investigation · doi:10.4155/cli.13.8 · Cited by 17
Hernaus, D., Quaedflieg, C. W. E. M., Offermann, J. S., Santa, M. M. C., & van Amelsvoort, T. (2017) · Social Cognitive and Affective Neuroscience · doi:10.1093/scan/nsx122 · Cited by 16
“The N-back task (Gevins and Cutillo, 1993) is a well-validated neuroimaging paradigm, previously shown to reliably increase fronto-parietal activity (Owen et al., 2005) and sensitive to changes in catecholamine function (Apud et al., 2007; Garrett et al., 2015).”
MethodAshare, R. L., Wileyto, E. P., Ruparel, K., Goelz, P. M., Hopson, R. D., Valdez, J. N., Gur, R. C., Loughead, J., & Lerman, C. E. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2013.09.003 · Cited by 18
“A dosetapering regimen was utilized on days 9–11 to reduce adverse effects associated with discontinuation of tolcapone (Apud et al., 2007).”
BackgroundMethodInfluentialBowers, H. E., Smith, D., de la Salle, S., Choueiry, J., Impey, D., Philippe, T. J., Dort, H., Millar, A., Daigle, M., Albert, P. R., et al. (2015) · Genes Brain & Behavior · doi:10.1111/gbb.12226 · Cited by 20
“…previous fMRI studies on acute nicotine dosing in healthy volunteers (Herman et al. 2013), dopamimetics (Hamidovic et al. 2010; Mattay et al. 2003) and COMT inhibitors (Apud et al. 2007; Farrell et al. 2012; Giakoumaki et al. 2008) generally support the inverted-U model of dopamine function.”
BackgroundIhne, J. L., Gallagher, N. M., Sullivan, M. E., Callicott, J. H., & Green, A. E. (2015) · Cortex · doi:10.1016/j.cortex.2015.10.025 · Cited by 16
Self-citationRobbins, T. W. (2009) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195373035.003.0014 · Cited by 18
Mih, N., Brunk, E., Bordbar, A., & Palsson, B. Ø. (2016) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005039 · Cited by 16
“These findings are consistent with previous studies related to entacapone, which report decreased efficacy of entacapone in individuals with the SNP (Met108) [52], though it may be dependent on different human-specific characteristics [84] and tolcapone, which has a reported increased efficacy in individuals with the…”
The current and potential impact of genetics and genomics on neuropsychopharmacology
Harrison, P. J. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.02.005 · Cited by 14
“Prior studies had hinted at a similar phenomenon but had not shown such a marked or statistically robust effect (Apud et al., 2007; Giakoumaki et al., 2008).”
ResultCan genetics inform the management of cognitive deficits in schizophrenia?
Vyas, N. S., Shamsi, S. A. R., Malhotra, A. K., Aitchison, K. J., & Kumari, V. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881111434623 · Cited by 15
“Another study showed that tolcapone, an inhibitor of COMT used in Parkinson’s disease, was associated with improvement on a measure of verbal memory in Val158 carriers, with the Met158 homozygotes having worse performance (Apud et al., 2007).”
BackgroundGibbs, A. A., Naudts, K. H., Azevedo, R. T., & David, A. S. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2009.12.007 · Cited by 14
Sambataro, F., Pennuto, M., & Wolf, R. C. (2012) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152712800672463 · Cited by 14
Gallrein, C., Meyer, D. H., Woitzat, Y., Ramirez-Ramirez, V., Vuong-Brender, T. T. K., Kirstein, J., & Schumacher, B. (2026) · Nature Aging · doi:10.1038/s43587-026-01067-5 · Cited by 14
“…spatial learning as well as memory deficits in rats 90 ; dibutyryl-cAMP-Na (dBcAMP) elevates cAMP levels and protects against neurodegeneration in stab wound or kainic acid injuries 91 ; and the catecholamine-O -methyltransferase inhibitor tolcapone was shown to improve cognitive function 92 .”
Ge, L., Wu, H., Pan, S., Huang, L., Sun, P. G., Liang, Q., Pang, G.-F., Lv, Z., Hu, C., Liu, C., et al. (2015) · PubMed · Cited by 15
Talpos, J. C. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.04.014 · Cited by 13
Potentiation of prefrontal cortex dopamine function by the novel cognitive enhancer d-govadine
Nesbit, M. O., Ahn, S., Zou, H., Floresco, S., & Phillips, A. G. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.109849 · Cited by 12
Ranganathan, M., Aquino, J. P. D., Cortes-Briones, J., Radhakrishnan, R., Pittman, B. P., Bhakta, S. G., & D’Souza, D. C. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05273-5 · Cited by 15
Martens, M., McConnell, F. A. K., Filippini, N., Mackay, C., Harrison, P. J., & Tunbridge, E. M. (2021) · NeuroImage · doi:10.1016/j.neuroimage.2021.117999 · Cited by 11
Gibbs, A. A., Bautista, C. E., Mowlem, F. D., Naudts, K. H., & Duka, D. (2014) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.130131 · Cited by 11
Iwaki, H., Tagawa, M., Iwasaki, K., Kawakami, K., & Nomoto, M. (2019) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2019.05.028 · Cited by 11
Use of magnetic resonance imaging in pharmacogenomics
Viviani, R., Lehmann, M., & Stingl, J. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12197 · Cited by 11
Huey, E. D., Fremont, R., Manoochehri, M., Gazes, Y., Lee, S., Cosentino, S., Tierney, M., Wassermann, E. M., Momeni, P., & Grafman, J. H. (2020) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.19100211 · Cited by 10
Troudet, R., Detrait, E., Hanon, É., & Lamberty, Y. (2015) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2015.08.012 · Cited by 12
Behandlung kognitiver Defizite bei Schizophrenie: Teil II: Pharmakologische Strategien
Roesch-Ely, D., Pfueller, U., Mundt, C., Müller, U., & Weisbrod, M. (2010) · Der Nervenarzt · doi:10.1007/s00115-009-2919-6 · Cited by 11
A systematic review of the cognitive effects of the COMT inhibitor, tolcapone, in adult humans
Kings, E., Ioannidis, K., Grant, J. E., & Chamberlain, S. R. (2024) · CNS Spectrums · doi:10.1017/s1092852924000130 · Cited by 9
“Our second hypothesis was also only partlysupported:particularly forworking memorytasks, 13,19,20 there was evidence that effects of tolcapone operated according to an inverted “ U ” model of human cognition.”
BackgroundResultDESI-MSI-based technique to unravel spatial distribution of COMT inhibitor Tolcapone
Rebouta, J., Dória, M. L., Campos, F., Araújo, F., & Loureiro, A. I. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.122607 · Cited by 9
Zhong, J. Y. (2022) · Behavioral Neuroscience · doi:10.1037/bne0000537 · Cited by 11
Kleptomania treated with tolcapone, a catechol-O-methyl-transferase (COMT) inhibitor
Grant, J. E. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.11.003 · Cited by 9
“…inhibition is felt to be the basis for top-down control of motivated behaviors (Rolls, 2000; Miller and Cohen, 2001) Tolcapone has shown benefit in improving performance on tests of executive functioning and the efficiency of cortical information processing in healthy adults (Apud et al., 2007).”
BackgroundIntroduction: Genes, cognition and neuropsychiatry
Elvevåg, B., & Weinberger, D. R. (2009) · Cognitive Neuropsychiatry · doi:10.1080/13546800903126016 · Cited by 10
“Indeed, especially in Val homoygotes, there are reports of marked improvements in working memory, executive function and prepulse inhibition behaviourally and in vivo in terms of PFC working memory ‘‘efficiency’’ (as assayed via fMRI) in healthy volunteers (Apud et al., 2007; Giakoumaki et al., 2008).”
BackgroundSelf-citationMehlman, M. J., & Berg, J. W. (2008) · The Journal of Law Medicine & Ethics · doi:10.1111/j.1748-720x.2008.303.x · Cited by 10
Reduced brain activation during inhibitory control in children with COMT Val/Val genotype
Cope, L. M., Hardee, J. E., Soules, M. E., Burmeister, M., Zucker, R. A., & Heitzeg, M. M. (2016) · Brain and Behavior · doi:10.1002/brb3.577 · Cited by 9
“…of healthy adult subjects in which the COMT enzyme was pharmacologically manipulated further supports this: Administration of tolcapone, a COMT enzyme inhibitor, improved executive functioning in subjects with the Val/Val genotype, but worsened performance in Met/Met subjects (Apud et al., 2007).”
Huey, E. D., Armstrong, N. M., Momeni, P., & Grafman, J. H. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.11.1367 · Cited by 11
“Another currently ongoing trial tests the effects of a medication, tolcapone, that probably increases dopamine selectively in the frontal lobes [48,49] and has shown an effect on executive function in healthy subjects, on behavior, cognition, and functional MRI findings in FTD patients [50,51] .”
BackgroundCan the Brain Be Relativistic?
Rastmanesh, R., & Pitkänen, M. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.659860 · Cited by 10
Clinical pharmacokinetics of levodopa and relevant add-on therapies for Parkinson’s disease
Müller, T. (2024) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2024.2428831 · Cited by 10
“One assumed, that glial COMT-I by tolcapone increases dopamine in the synaptic cleft and therefore will also improve motor behavior in PD patients similar to cognition and cortical information processing in normal human subjects [39,40].”
Putative cortical dopamine levels affect cortical recruitment during planning
Fallon, S. J., Hampshire, A., Williams‐Gray, C. H., Barker, R., & Owen, A. M. (2013) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2013.07.016 · Cited by 9
“Furthermore, this pattern of results is reversed by pharmacological manipulations that increase PFC DA levels (Apud et al., 2007; Farrell, Tunbridge, Braeutigam, & Harrison, 2012; Mattay et al., 2003).”
Lee, M. R., Gallen, C. L., Ross, T. J., Kurup, P. K., Salmeron, B. J., Hodgkinson, C. A., Goldman, D. A., Stein, E. A., & Enoch, M. (2013) · Genes Brain & Behavior · doi:10.1111/gbb.12027 · Cited by 8
“As the COMT inhibitor tolcapone has been shown to improve cognitive function (Apud et al. 2007; Giakoumaki et al. 2008) and reduce risk taking behavior (Farrell et al. 2012) in Val/Val allele individuals, such a strategy in smokers may also reduce responses to negative feedback and decrease…”
BackgroundMethodMihaylova, A., Zlatanova, H., Doncheva, N., Delev, D. P., & Kostadinov, I. (2019) · PubMed Central · doi:10.22038/ijbms.2019.33025.7890 · Cited by 8
“Clinical studies showed that tolcapone improves memory processed by the prefrontal cortex not only in patients with PD (13) but also in healthy humans (14).”
BackgroundPossible Treatment Concepts for the Levodopa-Related Hyperhomocysteinemia
Müller, T. H. (2009) · Cardiovascular Psychiatry and Neurology · doi:10.1155/2009/969752 · Cited by 11
Furman, D. J., Pappas, I., White, R. L., Kayser, A. S., & D’Esposito, M. (2021) · NeuroImage · doi:10.1016/j.neuroimage.2021.118472 · Cited by 7
Doyle, M. R., Dirik, S., Martinez, A. R., Hughes, T. E., Iyer, M. R., Sneddon, E. A., Seo, H., Cohen, S. M., & de Guglielmo, G. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109770 · Cited by 7
“…that CIE alters dopaminergic activity in the prefrontal cortex (Trantham-Davidson et al., 2014) and COMT inhibitors are used as cognitive enhancers (Apud et al., 2007; Bhakta et al., 2017; Gasparini et al., 1997), it is possible that regulating dopaminergic activity in the prefrontal cortex is…”
Wu, S., Upadhyay, N., Lu, J., Jiang, X., Li, S., Zhao, Q., Wang, J., Liang, X., Zhang, X., & Zhang, B. (2020) · Brain and Behavior · doi:10.1002/brb3.1784 · Cited by 6
Gründer, G., & Bartsch, T. (2014) · Der Nervenarzt · doi:10.1007/s00115-013-3977-3 · Cited by 13
HOW MIGRAINES IMPACT COGNITIVE FUNCTION: FINDINGS FROM THE BALTIMORE ECA
Vale, S. (2007) · Neurology · doi:10.1212/01.wnl.0000281352.37163.48 · Cited by 6
To what extent do neurobiological sleep-waking processes support psychoanalysis?
Gottesmann, C. (2010) · International review of neurobiology · doi:10.1016/s0074-7742(10)92012-6 · Cited by 5
Popławska-Domaszewicz, K., Limbachiya, N., Qamar, M. A., Batzu, L., Jones, S., Sauerbier, A., Rota, S., Lau, Y. H., & Chaudhuri, К. R. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14090939 · Cited by 5
“Entacapone and the newer third-generation COMT inhibitor, Opicapone, are widely used in clinical practice, whereas Tolcapone is generally not recommended due to its hepatotoxic side effects [5,6].”
BackgroundMental Function as Genetic Expression: Emerging Insights From Cognitive Neurogenetics
Green, A. E., & Dunbar, K. N. (2012) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780199734689.013.0007 · Cited by 6
Pharmacogenomics and Psychiatric Clinical Care
Amato, R. J., Boland, J. R., Myer, N. M., Few, L. R., & Dowd, D. (2017) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20170928-01 · Cited by 6
Entacapone/Tolcapone/Opicapone for Treating Parkinson’s Disease
Müller, T. H. (2020) · Springer eBooks · doi:10.1007/978-3-319-56015-1_230-1 · Cited by 5
Cha, E., Ahn, H. J., Kang, W., Jung, K., Ohn, S. H., Bashir, S., & Yoo, W. (2022) · Medicine · doi:10.1097/md.0000000000029214 · Cited by 6
“6 Val group during adolescence with the opposite effect on the structure.([59,60]) The UF is a white matter tract that connects the VLPFC to the anterior temporal lobe, which is involved in memory, language, and social emotional processing.”
BackgroundFrontal Cortex Functioning in InfancyPreprint
Holmboe, K. (2017) · Thesis Commons (OSF Preprints) · doi:10.31237/osf.io/qe9ck · Cited by 5
Lee, T. T., Chana, G., Gorry, P. R., Ellett, A. M., Bousman, C., Churchill, M. J., Gray, L. R., & Everall, I. (2015) · Journal of NeuroVirology · doi:10.1007/s13365-015-0354-y · Cited by 4
“…effect of Tolcapone where cognitive performance was improved in Val/Val but not Met/Met individuals, further strengthening the notion of the inverted-Ushaped relation of the optimal dopamine level and cognitive performance (Apud et al, 2007; Bitsios and Roussos, 2011; Farrell et al, 2012).”
BackgroundHong, H., Kim, R. Y., Song, Y., Suh, C., Lee, H., Lyoo, I. K., Yoon, S. J., Lim, S. M., & Lee, S. L. (2022) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-022-01436-2 · Cited by 5
Poline, J., Breeze, J. L., & Frouin, V. (2015) · Biological magnetic resonance · doi:10.1007/978-1-4899-7591-1_24 · Cited by 4
Bhatt, T., Patel, B. M., & Patel, M. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819838-4.00028-6 · Cited by 3
Miranda, G. G., Gonen, C., Kraft, J. N., Rodrigue, K. M., & Kennedy, K. M. (2024) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2024.11.005 · Cited by 3
“…effects on various aspects of EF, including response times (Nagel et al., 2008), working memory accuracy (St ¨ ormer et al., 2012), set-shifting (Apud et al., 2007), sustained attention (Blasi et al., 2005), and cognitive flexibility (Barnett et al., 2007; Wishart et al., 2011), with Met…”
Rethinking the Contribution of Neuroimaging to Translation in Schizophrenia
Tost, H., Zangl, M., & Meyer‐Lindenberg, A. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-386945-6.00006-8 · Cited by 3
Diekhof, E. K., Geana, A., Ohm, F., Doll, B. B., & Frank, M. J. (2021) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2021.658769 · Cited by 5
“The COMT-Val158Met polymorphism codes for the activity of the dopamine-degrading enzyme catechol-o-methyltransferase (COMT) (Apud et al., 2007; Käenmäki et al., 2010), which is more active in the prefrontal cortex of carriers of the Val allele than of individuals homozygote for the Met allele.”
BackgroundPharmakotherapie kognitiver Störungen
Gründer, G. (2007) · Springer eBooks · doi:10.1007/978-3-540-71147-6_48 · Cited by 3
Müller, T. H. (2016) · Neurodegenerative Disease Management · doi:10.2217/nmt-2016-0025 · Cited by 3
Entacapone/Tolcapone/Opicapone for Treating Parkinson’s Disease
Müller, T. H. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_230 · Cited by 2
The Role of Dopamine Signaling and Neuroinflammation in Age‐Related Cognitive Dysfunction
Bowen, J., Hanna, K., Young, A. M. J., Helfer, G., & McLean, S. L. (2026) · Brain and Behavior · doi:10.1002/brb3.71395 · Cited by 2
“Indeed, pharmacological inhibition of COMT has been shown to enhance cortical processing in both rodents and humans (Apud et al. 2006 ; Laatikainen et al. 2013 ; Tunbridge 2004 ), supporting its role in maintaining dopaminergic tone in the aging brain.”
IMAGING BIOMARKERS IN DRUG DEVELOPMENT: CASE STUDIES
Tauscher, J. T., & Schwarz, A. J. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9780511976087.012 · Cited by 2
Imaging Genetics: Unraveling the Neurogenetic Risk Architecture of Mental Illness
Tost, H., Böhringer, A., & Meyer‐Lindenberg, A. (2014) · Springer eBooks · doi:10.1007/978-3-642-54542-9_7 · Cited by 3
10.4 Dopamine Dysfunction in Schizophrenia: From Genetic Susceptibility to Cognitive Impairment
Tost, H., Hakimi, S., & Meyer‐Lindenberg, A. (2009) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195373035.003.0039 · Cited by 2
Metadata
- Authors
- Apud, J. A., Mattay, V., Chen, J., Kolachana, B. S., Callicott, J. H., Rasetti, R., Alce, G., Iudicello, J. E., Akbar, N., Egan, M. F., Goldberg, T. E., & Weinberger, D. R.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Weinberger, Daniel R
- ORCID
- Venue
- Neuropsychopharmacology
- Published
- 2006-10-25
- Volume
- 32
- Issue
- 5
- Pages
- 1011-1020
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2123236884
- Cited by
- 242
- References
- 39
- Citations by year
- 2026: 4 · 2025: 1 · 2024: 9 · 2023: 4 · 2022: 19 · 2021: 9 · 2020: 12 · 2019: 4 · 2018: 7 · 2017: 12 · 2016: 14 · 2015: 13 · 2014: 6 · 2013: 25 · 2012: 18
- FWCI
- 6.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cognitive Neuroscience › Neural and Behavioral Psychology Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- tolcapone, COMT inhibition, COMT Val158Met polymorphism, prefrontal cortex, executive function, working memory, verbal episodic memory, dopamine signaling
- MeSH terms
- Tolcapone, Adult, Benzophenones, Brain Mapping, Catechol O-Methyltransferase, Cognition, Double-Blind Method, Enzyme Inhibitors, Female, Genotype, Humans, Magnetic Resonance Imaging, Male, Memory, Middle Aged, Neuropsychological Tests, Nitrophenols, Placebos, Reference Values, Treatment Outcome, Prefrontal Cortex, Cross-Over Studies, Amino Acid Substitution, Catechol O-Methyltransferase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.